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Nanjing, Shenyang, Beijing, and Tianjin, ChinaObjectives The present study aimed to establish a risk score using a simple calculation with an
enhanced predictive value for major adverse cardiac events (MACE) in patients with unprotected
left main coronary artery (UPLMCA) disease after the implantation of a drug-eluting stent (DES).
Background The anatomic-, clinical-, and procedure-based NERS (New Risk Stratiﬁcation) score was
superior to the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS and
Cardiac Surgery) score in predicting MACE after stenting UPLMCA. The complexity of the calculation
was its major limitation.
Methods The NERS score II was derived from our previous 2 studies and externally compared with the
NERS and SYNTAX scores in 1,463 patients with UPLMCA disease who underwent implantation of
a DES in a prospective, multicenter registry trial. The primary endpoint was MACE at 1 year after the
index procedure, including myocardial infarction, cardiac death, and target vessel revascularization.
Results The NERS score II system consisted of 16 (7 clinical and 9 angiographic) variables. A NERS
score II 19 demonstrated enhanced MACE sensitivity and speciﬁcity of 84.0% and 76.0% (MACE as
the state variable), respectively, which were similar to the NERS score but signiﬁcantly higher
compared with the SYNTAX score. A NERS score II 19 was the only independent predictor of
cumulative MACE (hazard ratio: 3.27; 95% conﬁdence interval [CI]: 1.86 to 5.23; p  0.001) and stent
thrombosis (odds ratio: 22.15; 95% CI: 12.47 to 57.92; p  0.001) at follow-up.
Conclusions The NERS score II, similar to the conventional NERS score, is more predictive of MACE
than the SYNTAX score in UPLMCA patients after implantation of a DES. (J Am Coll Cardiol Intv
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Table 1. Variables in the NERS Score II
Deﬁnition(s) Score
Clinical (n ¼ 7)
Age, 75 yrs Plus 1 score per 5-year increment 1.34
LVEF, 40% Plus 1 score per 10% reduction 2.03
AMI, <12 h AMI within 12 h 3.65
Cardiogenic shock By AHA/ACC criteria 4.17
Diabetes Diagnostic diabetes 1.47
eGFR, 60 ml/min Plus 1.5 score per 10 ml/min reduction 1.82
Peripheral artery disease,
DS >70%
DS >70% 1.74
LMT lesions (n ¼ 5)
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1234Risk stratiﬁcations for patients with unprotected left main
coronary artery (UPLMCA) disease have been established as
important tools to predict clinical events after stenting
UPLMCA (1–3). Our previous study has shown that, with
the combination of clinical and procedural variables, the
NERS (New Risk Stratiﬁcation) score is more predictive of
major adverse cardiac events (MACE) than the SYNTAX
(Synergy Between Percutaneous Coronary Intervention
With TAXUS and Cardiac Surgery) score (2). However, the
complex calculation of the NERS score limits its routine use
in everyday practice.
The purpose of the present study was to enhanceOstial LM or body shaft Lesion at ostium or at the body of LM 1.18
Distal bifurcation*/trifurcationy Bifurcation/trifurcation lesions 12.90
Distal nonbifurcation Medina 1,1,0; 0,0,1 8.67
LMT-CTO CTO 3 month in LM 13.73
Severe LM calciﬁcation Needing rota (balloon failed to work) 6.13
Downstream lesions (n ¼ 4)
RCAz/LCXx non-CTO lesion TIMI ﬂow grade 2 1.27
LAD, non-CTO lesions TIMI ﬂow grade 2 5.21
CTO in either LCXx or RCAz TIMI ﬂow grade 0-1, 3 months 3.27
CTO in LAD TIMI ﬂow grade 0-1, 3 months 5.49
*Medina 0,1,1 or 1,1,1. yMedina 0,1,1,1 or 1,1,1,1. zRight dominance. xLeft dominance.
AHA/ACC ¼ American Heart Association/American College of Cardiology; AMI ¼ acute
myocardial infarction; CTO ¼ chronic total occlusion; DS ¼ diameter stenosis; eGFR ¼ esti-
mated glomerular ﬁltration rate; LAD ¼ left anterior descending coronary artery; LCX ¼ left
circumﬂex coronary artery; LM ¼ left main coronary artery; LMT ¼ left main trunk; LVEF ¼ left
ventricular ejection fraction; NERS ¼ New Risk Stratiﬁcation; RCA ¼ right coronary artery;
rota ¼ rotational atherectomy; TIMI ¼ Thrombolysis In Myocardial Infarction.
Abbreviations
and Acronyms
AUC = area under the curve
CABG = coronary artery
bypass graft surgery
CI = conﬁdence interval
CTO = chronic total occlusion
DES = drug-eluting stent(s)
eGFR = estimated glomerular
ﬁltration rate
IVUS = intravascular
ultrasound
LM = left main coronary
artery
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ROC = receiver-operating
characteristic
ST = stent thrombosis
TVR = target vessel
revascularization
UPLMCA = unprotected left
main coronary artery
VD = vessel diseasethe anatomic- and clinical-based
NERS score to create the NERS
score II.TheNERSscore II should
provide the equivalent power to
the conventional NERS score in
the prediction of clinical outcomes
after stenting UPLMCA, thus
aiding appropriately individual-
ized decision making.
Methods
Patient population. Between
March 19, 2003, and December
30, 2011, 2,060 patients with
UPLMCA who underwent per-
cutaneous coronary intervention
(PCI) with implantation of a
drug-eluting stent (DES) were
prospectively studied at 6 tertiary
centers. Of these patients, 597
patientsd260 in the DISTAL
(Drug-Eluting Stent for the
Treatment of Left Main Disease)
study (3) and 337 in the NERS
study (2)dwere excluded from
the current study. Finally, 1,463
patients were enrolled in this
study. The study protocol wasapproved by the ethics committee of each participating
center.
The revascularization strategy for each patient with
UPLMCA was jointly formulated by cardiologists and
cardiac surgeons, based upon clinical and angiographic
features. UPLMCA patients undergoing stent implantation
were consecutively enrolled, and all data were entered into
a dedicated database.
NERS Score II. The NERS score (2) was derived from 260
UPLMCA patients included in the DISTAL study (3) and
was externally tested in 337 patients in the NERS study. Of
54 variables (including 17 clinical, 4 procedural, and 33
angiographic variables) in the NERS score, several variablesremained repeatedly calculated. For example, “requiring an
intra-aortic balloon pump” overlapped with “cardiogenic
shock” and “lower left ventricular ejection fraction,” “not
taking a statin” overlapped with “a higher low-density
lipoprotein level.” Similarly, lesions in non-left main (LM)
vessels were grouped according to chronic total occlusion
(CTO) and non-CTO lesions, respectively, and lesions
speciﬁcities in the right coronary artery and the left
circumﬂex coronary artery had similar predictive value of
MACE. Therefore, the 54 variables included in the NERS
score were regrouped into 7 clinical variables, 5 angiographic
variables for LM, and 4 angiographic variables for non-LM
vessels. These new variables and the conventional 54 vari-
ables were put into the model and analyzed in 597 patients
by logistic regression, and the probability score for each
variable was then calculated. Variables with a p value <0.01
were considered signiﬁcant predictors and formed the
NERS score II. Finally, the NERS score II consisted of 16
variables (7 clinical, 5 lesion variables for LM, and 4 lesion
variables for non-LM vessels) (Table 1). Similar to the
NERS score, for ostial and shaft or distal LM stenosis, the
highest score for distal LM lesions was considered the ﬁnal
score for the LM. Similarly, tandem stenoses within 1 vessel,
such as CTO with bifurcation, were scored as the highest
score of any lesion (i.e., CTO).
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1235Endpoints. The primary endpoint was the rate of MACE,
deﬁned as cardiogenic death, myocardial infarction (MI), or
target vessel revascularization (TVR) at follow-up. Stent
thrombosis (ST) was assessed as a secondary event.
Procedural and periprocedural medications. After receiving
written informed consent, all interventional procedures were
performed according to the current standard guidelines.
Decisions regarding glycoprotein IIb/IIIa inhibitors, low-
molecular-weight heparin, stent type, pre-dilation, and
intravascular ultrasound (IVUS) were at the operator’s
discretion. All patients were advised to take lifelong aspirin
(100 mg daily) therapy. Thienopyridine therapies consisted
of 12 months of clopidogrel (75 mg/day).
Deﬁnitions. UPLMCA was deﬁned as diameter stenosis
50% in the absence of a patent bypass conduit to the left
system. Lesion variables, including isolated UPLMCA
disease, UPLMCA with 1- to 3-vessel disease (VD),
bifurcation or trifurcation lesions, CTO, severe calciﬁcation,
severe tortuosity, thrombus, dominance, lesion number, and
diseased vessel number, were classiﬁed according to the
SYNTAX deﬁnitions (1). Lesion classiﬁcations in the LM,
downstream lesions, restenosis in the LM, complete revas-
cularization, stent number, stent length, and stent diameter
were calculated on the basis of the criteria in the DISTAL
study (3).
All deaths were considered cardiac unless a noncardiac
cause was established clinically or at autopsy. MI was
diagnosed according to the third universal deﬁnition (4). In-
stent restenosis was deﬁned as >50% diameter stenosis at
follow-up; TVR was considered as repeat PCI or coronary
artery bypass graft surgery (CABG) involving the index
vessel. Stent thrombosis (ST) was classiﬁed according to the
Academic Research Consortium deﬁnitions as deﬁnite,
probable, or possible and as early (0 to 30 days), late (31 to
360 days), or very late (>360 days) (5). Angiographic success
was deﬁned as residual stenosis <10% with TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade 3 in
both branches. Procedural success referred to angiographic
success in the absence of in-hospital MACE.
Clinical follow-up. Phone interviews were conducted
monthly for 12 months and at 6-month intervals thereafter;
clinical assessment was performed for suspected ischemic
symptomatology. Clinical events were evaluated by an
independent committee from 3 non-participating institu-
tions; all interventionalists and committee members had free
access to the database.
Quantitative coronary angiographic analyses. Repeat angi-
ography at 6 months after the index procedure was scheduled
unless clinically indicated earlier. Quantitative coronary
angiographic analysis at baseline, post-stenting, and at
follow-up were performed by the China Cardiovascular
Research Foundation using edge-detection techniques
(CAAS II, version 5.0, Pie Medical, Maastricht, the
Netherlands). Angiographic measurements included thestented segment as well as margins 5 mm proximal and distal
to the stent edge.
All scores were calculated by 3 technicians (Ms. Tian Xu,
Ms. Jing Kan, and Ms. Ling Lin from Nanjing First
Hospital, Nanjing Medical University) who were blinded to
the study design. The mean score was used, t as the ﬁnal
score. The interobserver and intraobserver variability calcu-
lated by Kappa analysis was 6% and 11%, respectively.
Statistical analysis. Continuous variables were expressed as
mean  SD and were compared using the Student t test.
Categorical variables were presented as counts and
percentages, and were compared using the chi-square test or
Fisher exact test. Survival curves were generated by the
Kaplan-Meier method, and survival among groups was
compared using the log-rank test. Cox proportional hazards
models were used to assess risk factors for adverse events.
Multivariate analysis, with all signiﬁcant variables (deﬁned
as p < 0.05 for the association), was performed to adjust for
possible confounders and identify independent predictors of
adverse events. Sensitivity, speciﬁcity, false-positive, and
false-negative, and positive and negative predictive values
were calculated and analyzed by crosstable analysis after
adjusting the model for the speciﬁc variables. Receiver-
operating characteristic (ROC) curves for the NERS score
II, the NERS score, and the SYNTAX scores were gener-
ated; the area under the curve (AUC) for each scoring
method and endpoint was compared with the null hypoth-
esis true area (0.5), and the 1  speciﬁcity, sensitivity, 95%
conﬁdence interval (CI), and signiﬁcance were determined.
The value corresponding to the highest accuracy (i.e.,
minimal false-negative and false-positive rates) was chosen
as the optimal cutoff value. To evaluate differences in the
AUCs and standard errors from ROC curves between the 3
scoring systems using the Delong method (2), all variables,
including cumulative MACE, ST, TVR for LM, MI, and
cardiac death, were entered into Analyse-it (Analyse-it
Software, version 3.0, Hearne Scientiﬁc Software, Mel-
bourne, Australia). A p value <0.05 was considered statis-
tically signiﬁcant. All statistical tests were 2-tailed. Statistical
analyses were performed using SPSS version 16.0 (SPSS,
Chicago, Illinois).
Results
Baseline clinical characteristics. In total, 366 patients
(25.0%) had decreased LVEF (<40%), with New York
Heart Association functional class III to IV in 191 (13.1%)
patients. Renal dysfunction (deﬁned as an estimated
glomerular ﬁltration rate [eGFR] <60 ml/min/1.73 m2) was
observed in 139 (12.4%) patients (Table 2).
Baseline angiographic and procedural characteristics. Emer-
gency LM stenting was required in 22 patients (6.5%).
LM-CTO lesions were rare (2.0%); however, 23.0% had
non–LM-CTO lesions (Table 3). Most UPLMCAs
Table 2. Baseline Characteristics of Overall Patients
Age, yrs 64.5  10.6
Men 1,125 (76.9)
Height, cm 167.8  7.1
Weight, kg 69.5  11.1
Hypertension 704 (62.6)
Systolic blood pressure, mm Hg 134.1  20.9
Diastolic blood pressure, mm Hg 79.1  12.2
Diabetes 434 (29.7)
Fasting blood glucose, mmol/l 6.1  2.3
On insulin 104 (11.2)
Hyperlipidemia 705 (49.1)
Total cholesterol, mmol/l 4.4  1.3
Lower-density lipid, mmol/l 2.6  2.3
Peripheral arterial disease 64 (9.1)
Family history of CAD 65 (7.8)
Current smoker 614 (42.2)
Taking statin >2 weeks 519 (35.9)
Clinical presentation
Acute myocardial infarction 331 (22.6)
ST-segment elevation myocardial infarction 206 (14.1)
Non–ST-segment elevation myocardial infarction 125 (8.5)
Previous myocardial infarction 250 (17.1)
Previous percutaneous coronary intervention 11 (1.6)
Previous coronary artery bypass graft 104 (14.9)
NYHA functional class III–IV 191 (13.1)
Left ventricular ejection fraction <40% 366 (25.0)
Cardiogenic shock 18 (1.2)
Serum creatinine, mmol/l 90.8  31.2
eGFR, ml/min/1.73 m2 76.7  24.4
<60 ml/min/1.73 m2 139 (12.4)
Values are mean  SD or n (%).
CAD ¼ coronary artery disease; NYHA ¼ New York Heart Association; other abbreviations as
in Table 1.
Table 3. Lesions and Procedural Characteristics
Right dominance 1,377 (94.1)
Left main
Ostial 435 (29.7)
Body 427 (29.2)
Whole shaft 213 (14.6)
Distal nonbifurcation 355 (24.3)
Distal bifurcation 773 (52.8)
Chronic total occlusion 29 (2.0)
2/3-vessel disease 1,249 (85.4)
Long lesions in RCA or LCX 686 (46.9)
Long lesions in LAD 524 (35.8)
Patent graft in RCA 32 (2.2)
Collaterals from RCA 460 (31.4)
Prior TIMI ﬂow grade 3 in LM 1,411 (96.7)
CTO in non-left main 337 (23.0)
CTO in RCA 153 (10.5)
CTO in LAD 225 (15.4)
Successful recanalization 290 (86.0)
Temporary pacing 20 (1.4)
Rotational atherectomy for LM 17 (1.2)
Intra-aortic balloon pump 88 (7.8)
2-stent for distal LM lesions 479 (32.7)
Classic crush 87 (18.2)
T 101 (21.1)
DK crush 120 (25.1)
Culotte 153 (31.9)
Kissing stenting 18 (3.8)
Stents in LM per patient
Stents, n 1.3  0.50
Diameter, mm 3.47  0.42
Length, mm 30.09  14.24
Overall, stents per patient
Stents, n 3.52  1.98
Diameter, mm 3.2  0.39
Length, mm 89.64  55.68
Post-stenting TIMI ﬂow grade 3 in LM 1,461 (99.9)
IVUS guidance 213 (14.6)
Angiographic success
LM 1,373 (93.9)
Non-LM 1,372 (93.8)
Contrast volume, ml 238  110
Values are n (%) or mean  SD.
DK¼ double kissing; IVUS¼ intravascular ultrasound; other abbreviations as in Tables 1 and 2.
Chen et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 2 , 2 0 1 3
The NERS Score II D E C E M B E R 2 0 1 3 : 1 2 3 3 – 4 1
1236(77.1%) were distal; 85.4% of patients had 2-VD or 3-VD
and required a greater number of stents. Staged procedures
were performed in 79.6% of patients. IVUS-guided proce-
dures were performed in 14.6% of patients. In total, 2-stent
techniques were used in 479 (23.7%) patients. Overall, the
LM stent diameter and length were 3.47  0.42 mm and
30.09  14.24 mm, respectively. Finally, TIMI ﬂow grade 3
in the LM was achieved in 1,461 (99.9%) patients, and
angiographic success for non-LM lesions was achieved in
1,373 (93.9%) patients.
Variables in the NERS II scoring system. The NERS score II
system consisted of 7 clinical and 9 (5 for LM and 4 for
non-LM) angiographic variables (Table 1).
Quantitative coronary angiography and clinical outcomes.
An 8-month angiographic follow-up (204  27 days post-
procedure) was performed in 1,021 (69.8%) patients
(Table 4). One-year follow-up data were available for all
patients, and the cumulative rates of MI, TVR, and cardiac
mortality were 2.2%, 8.3%, and 3.1%, respectively. The ﬁnal
cumulative MACE rate of 11.6% was driven primarily bysubsequent TVR. The overall ST rate was 1.8% (deﬁnite
1.0%, probable 0.4%, and possible 0.4%).
Comparison of the NERS score II and the conventional NERS
and SYNTAX scores. When in-hospital events were consid-
ered as state variables, the AUC by the NERS score II
(Table 5) was signiﬁcant for MI, MACE, and ST; the AUC
by the NERS score was signiﬁcant for MI and MACE; and
by contrast, the AUC by the SYNTAX score was only
signiﬁcant for MACE.
Table 4. Clinical Outcomes at 1 Year
Intraprocedural
Acute closure 14 (1.0)
Contrast-induced nephropathy 79 (12.5)
In-hospital
Cardiac death 13 (0.9)
MI 19 (1.3)
STEMI 7 (0.5)
NSTEMI 12 (0.8)
TLR 19 (1.3)
CABG 12 (0.8)
TVR 22 (1.5)
MACE 41 (2.8)
ST 9 (0.6)
Procedural success 679 (97.2)
At 1-year follow-up
Cardiac death 45 (3.1)
MI 25 (2.2)
STEMI 17 (1.2)
NSTEMI 12 (0.8)
TLR 97 (6.6)
CABG 21 (1.4)
TVR 121 (8.3)
MACE 169 (11.6)
ST 27 (1.8)
Deﬁnite 15 (1.0)
Probable 6 (0.4)
Possible 6 (0.4)
Values are n (%).
CABG ¼ coronary artery graft bypass; MACE ¼ major adverse cardiac events; MI ¼
myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; ST ¼ stent
thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; TLR ¼ target lesion revas-
cularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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1237At the end of follow-up, there were signiﬁcant differences
in the AUCs for MI, TVR, MACE, and ST between the
NERS score II or the conventional NERS score and the
SYNTAX score (Fig. 1). However, the AUC for cardiac
death using the conventional NERS score was not signiﬁ-
cant compared with the SYNTAX score (0.75, 95% CI:
0.67 to 0.83 vs. 0.69, 95% CI: 0.60 to 0.71, respectively,
p ¼ 0.0543).
Comparisons of subgroups stratiﬁed by the NERS and
SYNTAX scores. Per the ROC curve, a value of 19 stratiﬁed
the scores as NERS II-lower (<19) and NERS II-higher
(19). The Kaplan-Meier analysis demonstrated that in-
hospital MACE-free survival differed signiﬁcantly between
the NERS II-lower (99.0%) and NERS II-higher subgroups
(88.2%, p < 0.001) (Fig. 2), and between the NERS-lower
(96.3%) and NERS-higher (90.4%, p ¼ 0.001) subgroups.
This difference was sustained throughout the entire follow-
up period. By contrast, in-hospital MACE-free survival was
similar between the SYNTAX-lower (96.7%) and SYNTAX-
higher (93.3%, p ¼ 0.085) subgroups. The cumulative
MACE-free survival rate was signiﬁcantly different betweenthe SYNTAX-lower (99.1%) and SYNTAX-higher (87.3%,
p ¼ 0.039) subgroups.
A regression analysis demonstrated that a NERS score II
19 was the only independent predictor of cumulative
MACE (hazard ratio: 3.27; 95% CI: 1.86 to 5.23; p 
0.001) and ST (odds ratio: 22.15; 95% CI: 12.47 to 57.92;
p  0.001) at follow-up.
Discussion
The major ﬁndings of the present study are as follows:
1) after several baseline clinical or lesion variables and
procedural variables were excluded from the scoring system,
the simpliﬁed NERS score II had at least equivalent value to
the conventional NERS score in predicting clinical
outcomes for UPLMCA patients; and 2) the NERS score II
and conventional NERS score were superior to the
anatomic-based SYNTAX score in predicting clinical
events, indicating that the clinical factors had a direct impact
on determining clinical predictions.
Direct comparison of the NERS score II with the conventional
NERS score. Our previous conventional NERS score (2)
highlighted the important role of utilizing clinical, anatomic,
and procedural variables in driving outcome prediction for
UPLMCA patients after implantation of a coronary stent,
a ﬁnding similar to that of the ACUITY (Acute Catheteri-
zation and Urgent Intervention Triage StrategY) trial (6). In
that study, among 6 risk scores, scores incorporating
clinical and angiographic variables (CCS [Canadian Cardio-
vascular Society] andNERS) showed thebest tradeoff between
discrimination and calibration for most endpoints, with the
best discrimination for all endpoints and good calibration for
most. However, the complexity of the conventional NERS
score and the SYNTAX score limited their extensive use in
everyday practice. Another disadvantage of the conventional
NERS score was that it was generated from a relatively small
UPLMCA patient population (n ¼ 260) and externally
validated in a small UPLMCA patient population (NERS
study, n ¼ 337), not in a larger UPLMCA patient pop-
ulation. An insight analysis into the NERS score demon-
strated that several variables overlapped with others. For
example, “multivessel disease” obviously covered “downstream
lesions” and “thrombus-containing lesions,” and the variable of
“positive biomarkers” was at least partially similar to “acute
myocardial infarction (within 12 h).” More importantly,
procedural factors (particularly “complex stenting techniques”
and “IVUS guidance”) were variables that should have been
excluded before the stenting procedures. Similarly, “whole-
stem lesions” was actually the same as “distal nonbifurcation
lesions.”Asa result, with all variables from theNERSstudy and
the DISTAL study retained in the new model, several new
variables, such as “eGFR 60 ml/min” (thought to be more
important than serum creatinine), were incorporated into a new
regression model (with 597 patients) for the NERS score II.
Table 5. Comparison of ROC Curves
NERS Score II NERS Score SYNTAX Score
Area 95% CI p Value Area 95% CI p Value Area 95% CI p Value
In-hospital
MI 0.80 0.72–0.88 0.042 0.77 0.69–0.85 0.041 0.61 0.50–0.68 0.059
Cardiac death 0.80 0.68–0.93 0.062 0.70 0.54–0.87 0.085 0.67 0.52–0.82 0.077
TVR 0.77 0.66–0.87 0.054 0.71 0.61–0.81 0.052 0.63 0.53–0.73 0.051
MACE 0.79 0.73–0.85 0.028 0.73 0.70–0.82 0.036 0.60 0.53–0.68 0.039
ST 0.85 0.76–0.93 0.043 0.77 0.61–0.94 0.082 0.69 0.52–0.86 0.088
At 1 year
MI 0.83 0.77–0.88 0.029 0.79 0.72–0.86 0.035 0.61 0.52–0.70 0.046
Cardiac death 0.81 0.74–0.88 0.037 0.75 0.67–0.83 0.042 0.69 0.60–0.71 0.046
TVR 0.79 0.75–0.83 0.020 0.76 0.72–0.80 0.021 0.58 0.53–0.63 0.027
MACE 0.81 0.78–0.85 0.017 0.77 0.74–0.81 0.019 0.60 0.56–0.65 0.024
ST 0.82 0.76–0.88 0.031 0.80 0.75–0.87 0.038 0.70 0.61–0.72 0.049
CI ¼ conﬁdence interval; ROC¼ receiver-operating characteristic; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac
Surgery; other abbreviations as in Tables 1 and 4.
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1238The latter was externally evaluated in an additional 1,463
UPLMCA patients. Here, an explanation why severe LM
calciﬁcation (deﬁned as the need of rotablation) was incorpo-
rated into NERS score II.
Notably, female sex was previously shown to have
a negative impact on clinical outcomes after either CABG or
PCI using DES (2,7–9), primarily because of increased
comorbidity and unfavorable plaque characteristics (10–12).
However, this “negative female phenomenon” was masked
in the NERS score II system. A potential explanation for
this discrepancy included, at least partially, the fact that
advanced lesions in women overlapped with clinical
(peripheral arterial disease, eGFR, diabetes, age, and LVEF)
and angiographic variables. Interestingly, diabetes was
a signiﬁcant predictor, although it demonstrated lower
scores for the conventional NERS score and the NERS
score II. The complex interplay between clinical and
angiographic variables may underlie these ﬁndings, similar to
the other variables (such as hypertension). It is plausible that
the NERS score II was not associated with the loss of the
predictive value. Additionally, the predictive power of the
conventional NERS score was maintained by the NERS
score II and enhanced the prediction of in-hospital MACE,
although the p value was only marginally signiﬁcant.
Comparison with the anatomic-based SYNTAX score. Again,
in line with our previous study, the present study demon-
strated enhanced sensitivity and speciﬁcity for the prediction
of cumulative MACE, ST, cardiogenic death, TVR, and MI
for the conventional NERS score and the NERS score II.
Two-level stratiﬁcations were used: all patients were divided
into lower (SYNTAX <22, NERS <25, and NERS II
<19) and higher (SYNTAX >22, NERS 25, and NERS
II 19) risk groups. Similar to the previous study, the
SYNTAX score did not predict in-hospital MACE, whichhad a rate of 96.7% in the SYNTAX-lower subgroup and
93.3% in the SYNTAX-higher subgroup (p ¼ 0.085).
Features of the NERS score II. Two important procedural
variables, that is, IVUS guidance and stenting techniques,
included in the NERS score were excluded from the NERS
score II. The importance of IVUS guidance during PCI has
been addressed in several studies (13,14), but controversy
still exists (15,16). Chen et al. (14) were the ﬁrst to report
that the IVUS-guided 2-stent technique was associated with
signiﬁcantly reduced late ST in patients with bifurcation
lesions, with a resultant reduction in ST-segment elevation
MI in 628 patients, which is similar to the ﬁndings reported
by 2 previous studies (17,18) conducted by Korean teams.
However, the impact of IVUS guidance in the present study
was minimized, possibly because IVUS guidance was less
frequently used (14.6%), and IVUS assessment was primarily
performed for 2-stent strategies, which accounted for only
32.7% of patients. However, the predictive power of the
NERS score II was similar to the conventional NERS score
(incorporating IVUS guidance), indicating that the impor-
tance of the IVUS assessment could have been masked by
lesion-speciﬁc factors and clinical parameters.
Furthermore, 2-stent strategies for UPLMCA patients
have been associated with an increased rate of worse clinical
events (2,3,19,20) and were also excluded from the NERS
score II. Indeed, the 2-stent techniques for the treatment of
overall bifurcation lesions (21) and UPLMCA distal bifur-
cation lesions (22) did not obtain the same clinical results. In
our previous study (23), 2-stent techniques for UPLMCA
bifurcation lesions had a higher rate of cumulative MACE
when compared with a 1-stent technique, but double-kissing
crush stenting was not inferior to the 1-stent strategy and
was superior to other 2-stent techniques (21,23). Similarly,
2-stent strategies were used only in the ﬁrst of 3 patients in
Figure 1. Comparison of NERS II With NERS and SYNTAX for Predicting 1-Year Events
The NERS (New Risk Stratiﬁcation) score II and the conventional NERS score had enhanced power in predicting 1-year myocardial infarction (MI), target vessel
revascularization (TVR), major adverse cardiac events (MACE), and stent thrombosis (ST) compared with the SYNTAX (Synergy Between Percutaneous Coronary
Intervention With TAXUS and Cardiac Surgery) score. However, there were no signiﬁcant differences in the prediction of 1-year cardiac death between the NERS score II
and the conventional NERS score, although the prediction signiﬁcantly differed between the NERS score II and the SYNTAX score and between the conventional NERS
score and the SYNTAX score.
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1239the present study, which may account for the lack of power
of stenting techniques in predicting clinical events.
To individualize decision making for treating LM
stenosis on the basis of a score, a scoring system free of
procedure-related variables is needed. Even though the
authors stress that procedure-related variables have been
removed in comparison to the NERS score, 1 anatomic,
procedure-related variable is still included in the revised
NERS score II (severe LM calciﬁcation, deﬁned as needing
rotablation). Rotablation is an important predictor of
MACE from SYNTAX (1) and our previous study (2).
According to the deﬁnition of rotablation from NERS score
II, needing rotablation included that balloon failed to pass or
to crack the angiography-deﬁned non-severe calciﬁcation
and that rotablation was used for angiography-deﬁned severe
calciﬁcation. Therefore, even though rotablation was only
used in 1.2% of patients as in the current study, it indeed
indicated the “real” calciﬁed lesions in LM.
Clinical relevance. The complexity of the calculation of
previous scoring systems limited their acceptance. The
NERS score II contains only 16 variables and allows the
realization of “real-time” scoring. Such convenient scoring is
easily performed bedside and would be meaningful to drivethe prediction of clinical outcomes. Most importantly, the
predictive value of the conventional NERS score was
maintained and further enhanced by the simpliﬁed NERS
score II. With the use of this simpliﬁed scoring system,
a calculator or smart phone software application could be
developed for the NERS score II system.
The current study demonstrated that the composite
MACE was acceptable (11.6%). However, even we did not
report the baseline characteristics and clinical events in
patients who received CABG, our results showed that
patients in NERS score II-higher subgroups had signiﬁ-
cantly higher composite MACE (69.4%), mainly driven by
target lesion revascularization/TVR. This result implied that
CABG should be recommended for high-risk patients
stratiﬁed by NERS score II, because the SYNTAX trial
indicated that high-risk patients had increased need of
revascularization. Furthermore, comparison of simple versus
complex stenting techniques for LM bifurcation lesions
would be a practical important issue in future studies.
Study limitations. First, its nonrandomized nature likely
inﬂuenced the power of the results. Second, procedural
variables reported to be related to the occurrence of worse
clinical events were excluded from the NERS score II.
Figure 2. MACE-Free Survival Rate in the Subgroups
When patients were classiﬁed using the 3 scoring systems, patients in high-risk subgroups according to the NERS score II and conventional score had increased in-
hospital (A, B) and 1-year (D, E) MACE. Although the SYNTAX-higher subgroup had increased 1-year MACE (F), there was no signiﬁcant difference in in-hospital MACE
between the SYNTAX-lower and SYNTAX-higher subgroups (C). Abbreviations as in Figure 1.
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1240However, our results showed the predictive value of the
NERS score II was at least equivalent to the conventional
NERS score (with procedural characteristics included). We
might boldly postulate that the interaction between clinical
and angiographic variables masks the importance of proce-
dural indexes. Finally, patients who received CABG were
not followed, and the intracenter MACE rate was not
calculated as presented by the SYNTAX trial.Conclusions
The NERS score II demonstrated improved predictive value
for primary endpoints after UPLMCA-PCI compared with
the SYNTAX score. Further, randomized studies are needed
to elucidate the role of the NERS score II in the decision ofPCI versus CABG for UPLMCA and complex anomalies
in a more diverse population.Acknowledgments
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